LGL Group (LGL) Projected to Post Quarterly Earnings on Monday

LGL Group (NYSEAMERICAN:LGL) will likely be releasing its Q4 2025 results after the market closes on Monday, March 30th. Analysts expect LGL Group to post earnings of $0.0651 per share and revenue of $9.10 million for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Friday, April 3, 2026 at 4:00 PM ET.

LGL Group Price Performance

Shares of LGL stock opened at $7.19 on Friday. The stock has a market cap of $46.95 million, a PE ratio of 42.30 and a beta of 0.31. The stock has a 50-day moving average of $7.12 and a 200-day moving average of $6.48. LGL Group has a one year low of $5.45 and a one year high of $9.74.

Insiders Place Their Bets

In other news, major shareholder Mario J. Gabelli bought 95,387 shares of the business’s stock in a transaction on Tuesday, December 30th. The shares were bought at an average cost of $4.75 per share, for a total transaction of $453,088.25. Following the completion of the acquisition, the insider owned 572,324 shares in the company, valued at approximately $2,718,539. This trade represents a 20.00% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 18.90% of the company’s stock.

Institutional Investors Weigh In On LGL Group

A hedge fund recently bought a new stake in LGL Group stock. Citadel Advisors LLC acquired a new stake in LGL Group, Inc. (The) (NYSEAMERICAN:LGL) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 13,515 shares of the industrial products company’s stock, valued at approximately $90,000. Citadel Advisors LLC owned approximately 0.25% of LGL Group at the end of the most recent reporting period. Hedge funds and other institutional investors own 30.28% of the company’s stock.

About LGL Group

LGL Group Inc is a United States–based company specializing in the development and commercialization of digital pathology and molecular imaging systems for research and clinical laboratories. The company’s core focus lies in enabling high-resolution visualization and quantitative analysis of tissue samples, helping scientists and pathologists accelerate biomarker discovery and diagnostic workflows. LGL Group’s platform combines advanced optics, automated slide scanning and image analysis software to deliver end-to-end solutions tailored to oncology, immunology and neuroscience research.

The company’s flagship offerings include whole-slide scanners capable of rapid, high-throughput scanning at resolutions suited for detailed morphometric and fluorescence studies.